Table 1 Patient characteristics.
Patient no. | Blast % | TP53 mutations (VAF%) | Other mutations | Previous treatments and responses |
|---|---|---|---|---|
26 | 50 | c.659 A > G p.Y220C (15) | NF1, PTPN11, NRAS, KRAS | Resistance to rituximab, palbociclib, and fulvestrant |
c.427 G > A p.V143M (14) | ||||
28 | 95 | c.733 G > A p.G245S (87) | NF1, TET2, DNMT3A | Resistance/relapsed AML. Resistance to chemotherapy and to VEN-based therapy |
29 | 89 | c.403 T > G p.C135G (86) | NF1, DNMT3A | Resistance/relapsed AML. Resistance to azacitidine/VEN, and BP1001 + decitabine |
30 | 85 | c.994-1 G > A (70) | NF1, ASXL1, CEBPA, KDM6A, RUNX1 | Resistance/relapsed AML. Resistance to 7 + 3, fludarabine- idarubicin-VEN, PLX51107 + azacitidine, daratumumab + VEN |
32 | 88 | c.742 C > T p.R248W (80) |  | Resistance to cladribine and low-dose cytarabine, azacitidine, VEN and pevonedistat, PLX51107 + azacitidine. |
33 | 65 | c.517 G > A p.V173M (46) |  | Resistance to azacitidine |
c.376-1 G > A (43) | ||||
34 | 94 | c.814 G > A p.V272M (22) | ASXL1, CEBPA | Newly diagnosed |
c.537 T > A p.H179Q (25) | ||||
35 | 78 | c.445dup p.S149fs (89) | BCOR, TET2, IDH2, STAG2, DNMT3A | Refractory AML. Resistance to fludarabine, cytarabine, filgrastim, idarubicin, VEN, 5-azacitidine plus VEN, LY3410738. |
